Teva Pharmaceutical Industries Ltd. — Report Publication Announcement 2004

Apr 29, 2004



C002	טבע תעשיות פרמצבטיות בע"מ		2
Public	TEVA- PHARMACEUTICAL INDUSTRIES LTD.
	2529	Corporation no: 520013954
	Stock Exchange/Market: טבע
	310
	380	P.O.B 3190 , Petach Tikva 49131 , ,
	Tel: 03-9267297 , 03-9267281 Fax: 03-9267429
	E.mail address: DORIT@TEVA.CO.IL	Date of transmission: 29/04/2004
		Time of broadcast: 13:40 13:38:09
		Reference: 2004-02-092991

Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000 The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on	TEVA ANNOUNCES APPROVAL OF FLUDARABINE PHOSPHATE INJECTION

Fludarabinefinal290404_isa.pdf

Please find attached a press release announced Today in the U.S. and its unofficial hebrew translation. The binding release is the english version.
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous name of reporting entity:
Date of revision of form structure: 28/12/2003
- - -
Name of the Signatory : Suesskind Dan Position of Signatory in the reporting corporation: Chief Financial Officer
Basel Telephone: 02-5892840 , Facsimile: 02-5892839 , E-mail: dan.suesskind@teva.co.il